Table 1.

T-cell proliferation assays, lymphocyte subsets, and vaccination responses before and after GT

	Before GT	After GT	Healthy control ranges for 3-d stimulation
T-cell proliferation
Spontaneous (cpm)	103	115*
PHA (cpm)	2490	50 349*	18 906-417 388
aCD3 (cpm)	226	22 699*	187-122 682
aCD3/aCD28 (cpm)	2186	52 068*	1202-213 904
Lymphocyte subsets
Total lymphocytes (×109/mL) (normal range: 1.0-2.8)	0.572	2.251†	1.469/1.11§
CD3 (×109/mL) (normal range: 0.7-2.1)	0.518	1.389†	0.789/0.723§
CD4 (×109/mL) (normal range: 0.3-1.4)	0.414	0.62†	0.407/0.409§
CD8 (×109/mL) (normal range: 0.2-0.9)	0.105	0.408†	0.252/0.23§
CD19 (×109/mL) (normal range: 0.1-0.5)	0.027	0.408†	0.407/0.409§
Vaccination responses
Total pneumococcal titres (mg/L) (protective levels >20 mg/L)	On immunoglobulin replacement therapy	4‡	43||
Pneumococcus serotype-specific responses (protective levels >0.35 mg/L)	On immunoglobulin replacement therapy	ND‡	Protective responses against 3/13 serotypes||
Tetanus toxoid (IU/mL) (protective levels: 0.1-0.7)	On immunoglobulin replacement therapy	0.14‡	2.51||

PHA, phytohemagglutinin.

^*16 months after GT.

^†6 months after GT.

^‡After GT, before vaccination.

^§11 months/16 months after GT.

^||After GT, after vaccination.